PDS Biotechnology Investor Relations Material
Latest events
Q4 2023
PDS Biotechnology
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from PDS Biotechnology Corporation
Access all reports
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its product pipeline includes thermo-sensitive PDS0101 (Amiket), which is in Phase 3 clinical trials for the treatment of patients with human papillomavirus associated disease; Discovery Program, a research and discovery program with a focus on tumor neo-antigens and synthetic vaccines; and Thermo-Oxidative Stress Induced Antigen(TOSIA) Program that combines chemical engineering, molecular biology, and immunology to discover tumor associated antigens.
Key slides for PDS Biotechnology Corporation
Study Update
PDS Biotechnology Corporation
Study Update
PDS Biotechnology Corporation
Latest articles
The Birkin Bag: The Story Behind the World's Most Desired Handbag
How the Birkin bag became the world's most sought-after handbag where even the wealthy must earn the right to own one.
12 Jul 2024
The 10 Largest Semiconductor Companies in the World
Discover the top 10 semiconductor companies by market cap, exploring their innovations and business models shaping the tech landscape.
10 Jul 2024
The Rise of Nubank: Changing Latin American Finance
Discover how Nubank revolutionized Latin American banking with innovation, backed by top investors like Berkshire Hathaway.
9 Jul 2024
Ticker symbol
PDSB
Country
🇺🇸 United States